PROVECTUS BIOPHARMACEUTICALS Business Summary

Provectus Biopharmaceuticals, Inc. (PVCT) is a clinical-stage biotechnology company that operates on a research and development-heavy business model, primarily generating revenue through strategic licensing agreements, research grants, and the formation of indication-specific subsidiaries, such as VisiRose for ophthalmology. The company’s primary business segments are centered on its proprietary halogenated xanthene (HX) platform, specifically its lead small-molecule immuno-catalyst, rose bengal sodium (RBS). These segments include oncology, where its flagship candidate PV-10 is tested for solid tumors like melanoma and liver cancer; dermatology, focused on PH-10 for inflammatory skin conditions; and ophthalmology. PVCT competes directly with immunotherapy and oncology-focused firms such as AVEO Oncology, Nanobiotix, and PDS Biotechnology. Within this landscape, Provectus occupies a specialized niche as a developer of intralesional and topical therapies that leverage a unique bifunctional mechanism of action to trigger immunogenic cell death. The leadership team is currently headed by Chief Executive Officer and Executive Chairman Ed Pershing, a CPA and co-founder of PYA, a top-tier healthcare consulting and accounting firm, who brings extensive experience in healthcare restructuring and long-range planning. He is supported by President Dominic Rodrigues, who previously led Rhisk Capital and holds advanced degrees from Wharton and MIT, and Chief Technology Officer Eric Wachter, Ph.D., a co-founder of the company’s precursor, Photogen Technologies, with over two decades of experience in pharmaceutical development. The board includes notable figures such as Dr. John W. Lacey III, the former Chief Medical Officer of the University of Tennessee Medical Center. Institutional backing is provided by regional entities including Home Federal Bank of Tennessee and Wealth Preservation Advisors, reflecting a concentrated investor base focused on the long-term clinical validation of the HX platform.